Paul Tudor Jones Tudor Investment Corp
Paul Tudor Jones is the founder of Tudor Investment Corporation and a pioneering macro trader. He rose to prominence after navigating the 1987 market crash successfully and has since built a multi-strategy firm spanning global markets. Jones is widely associated with discretionary macro trading, risk management discipline, and high-profile philanthropic efforts in education and the environment.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$53.9M |
| 2 |
COUP
Coupa Software Incorporated
COUP
|
+$32.1M |
| 3 |
COWN
Cowen Inc. Class A Common Stock
COWN
|
+$27.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$20.1M |
| 5 |
M&T Bank
MTB
|
+$20.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Y
Alleghany Corp
Y
|
+$93.4M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$71.8M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$42.9M |
| 4 |
ZEN
ZENDESK INC
ZEN
|
+$42.3M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$41.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.01% |
| 2 | Financials | 11.75% |
| 3 | Industrials | 10.85% |
| 4 | Healthcare | 10.32% |
| 5 | Consumer Discretionary | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Aurinia Pharmaceuticals
AUPH
$2.2B
| $181K | ﹤0.01% |
+41,839
| New | +$243K |
|
2152
Design Therapeutics
DSGN
$953M
| $181K | ﹤0.01% |
17,684
-10,182
| -37% | -$138K |
|
2153
Senseonics Holdings Inc
SENS
$496M
| $180K | ﹤0.01% |
8,719
-347
| -4% | -$8.01K |
|
2154
Coty
COTY
$2.46B
| $178K | ﹤0.01% |
20,828
-120,555
| -85% | -$885K |
|
|
BIG
2155
CALL
DELISTED
Big Lots, Inc.
BIG
| $178K | ﹤0.01% |
12,100
-9,900
| -45% | -$170K |
|
2156
Angi Inc
ANGI
$200M
| $174K | ﹤0.01% |
7,384
-4,691
| -39% | -$105K |
|
2157
PUT
Elanco Animal Health
ELAN
$12.2B
| $173K | ﹤0.01% |
+14,100
| New | +$176K |
|
|
SNPO
2158
DELISTED
Snap One Holdings Corp. Common Stock
SNPO
| $173K | ﹤0.01% |
23,345
-4,748
| -17% | -$43.8K |
|
2159
Ginkgo Bioworks
DNA
$457M
| $171K | ﹤0.01% |
+2,523
| New | +$232K |
|
2160
CALL
Kyndryl
KD
$2.78B
| $171K | ﹤0.01% |
+15,400
| New | +$155K |
|
|
TE
2161
T1 Energy
TE
$1.27B
| $171K | ﹤0.01% |
+19,673
| New | +$246K |
|
2162
Stoke Therapeutics
STOK
$2.09B
| $169K | ﹤0.01% |
18,313
| – | – |
|
2163
Park-Ohio Holdings
PKOH
$649M
| $167K | ﹤0.01% |
13,686
| – | – |
|
2164
Ardagh Metal Packaging
AMBP
$3.18B
| $166K | ﹤0.01% |
+34,589
| New | +$159K |
|
|
SVC
2165
Service Properties Trust
SVC
$1.04B
| $166K | ﹤0.01% |
+4,542
| New | +$167K |
|
|
MPT
2166
Medical Properties Trust
MPT
$2.46B
| $164K | ﹤0.01% |
14,762
-30,088
| -67% | -$350K |
|
|
2167
PUT
Kyndryl
KD
$2.78B
| $163K | ﹤0.01% |
+14,700
| New | +$148K |
|
|
USER
2168
DELISTED
UserTesting, Inc.
USER
| $161K | ﹤0.01% |
21,471
+2,331
| +12% | +$14.9K |
|
2169
AbCellera Biologics
ABCL
$3.44B
| $159K | ﹤0.01% |
15,648
+402
| +3% | +$4.64K |
|
|
TSP
2170
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $159K | ﹤0.01% |
+96,861
| New | +$345K |
|
2171
DocGo
DCGO
$37.8M
| $158K | ﹤0.01% |
22,329
| – | – |
|
|
ME
2172
DELISTED
23andMe Holding Co
ME
| $157K | ﹤0.01% |
3,635
-3,266
| -47% | -$190K |
|
2173
Stellantis
STLA
$19.7B
| $156K | ﹤0.01% |
+10,982
| New | +$153K |
|
2174
PUT
Applovin
APP
$99.9B
| $155K | ﹤0.01% |
+14,800
| New | +$217K |
|
2175
PUT
Frontline
FRO
$9.81B
| $155K | ﹤0.01% |
+12,800
| New | +$164K |
|
Similar funds
Paul Tudor Jones's Q4 2022 Portfolio in Review
As of Q4 2022, Paul Tudor Jones held 3,056 positions worth $5.06B, up 9.2% from $4.63B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Paul Tudor Jones deployed $198M of net new capital in Q4 2022, opening 801 new positions and adding to 766 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 648,672 shares worth $73.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 16% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was iShares MSCI Emerging Markets ETF, an estimated $39M trimmed.
- Paul Tudor Jones's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 648,672 shares worth $73.8M.
- Paul Tudor Jones added most to Coupa Software Incorporated in Q4 2022, an estimated $32.1M increase.
- Paul Tudor Jones's biggest Q4 2022 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $39M.
- Paul Tudor Jones fully exited Alleghany Corp in Q4 2022, selling an estimated $93.4M.
- Paul Tudor Jones's ten largest holdings make up 9.1% of its $5.06B portfolio in Q4 2022.
- Paul Tudor Jones opened 801 new positions and closed 756 in Q4 2022.
- Paul Tudor Jones's portfolio value rose 9.2% quarter-over-quarter to $5.06B.
Based on Tudor Investment Corp's 13F filing for Q4 2022, filed 14 Feb 2023.